NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report issued on Tuesday,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Several other equities research analysts have also commented on NRXP. HC Wainwright boosted their price target on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. D. Boral Capital restated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research report on Monday, March 16th. Finally, Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Trading Down 1.2%

Shares of NRXP opened at $2.38 on Tuesday. The firm has a market cap of $78.71 million, a P/E ratio of -1.71 and a beta of 1.97. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84. The stock’s 50 day moving average is $1.95 and its two-hundred day moving average is $2.43.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.28. The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $7.53 million. Equities research analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after buying an additional 1,018,853 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $994,000. Bleakley Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $318,000. Vanguard Group Inc. lifted its stake in shares of NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after buying an additional 82,781 shares in the last quarter. Finally, AdvisorShares Investments LLC boosted its position in NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after acquiring an additional 78,339 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.